Pheochromocytoma in MEN 2A syndrome. Study of 54 patients.
BACKGROUND
Pheochromocytoma occurs in nearly 50% of MEN 2A (multiple endocrine neoplasia, type 2A) cases. Many issues related to this tumor are still the subject of debate: the diagnostic management in patients who have had positive genetic study results (RET mutation), variations related to mutation, the best surgical option, and the real relapse rate during long-term follow-up. The aim of this study is to present our experience with this unusual disease, looking for answers to some of these questions.


METHODS
Of 169 patients belonging to 19 MEN 2A families, 54 (32%) presented with pheochromocytoma. The following variables have been studied: (1) clinical and diagnostic data [age, mutation, clinical features, results of catecholamines and catabolites in a 24-h urine sample, computerized tomography (CT) scan and iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy results, and the means of diagnostic, clinical, or genetic screening]; (2) surgical treatment; and (3) follow-up and recurrence. The mean follow-up time was 92.5 months (range: 12-120 months).


RESULTS
The mean age of the 54 patients was 37.9 years (range: 14-71 years); 33 were women. Most (96.3%) mutations were found in exon 11. The most frequent mutations were Cys634Tyr (in 33 cases [61.1%]) and Cys634Arg (in 14 [25.9%]). The diagnosis of pheocromocytoma was made after the diagnosis of MTC in 26 cases (48.2%), simultaneously in 21 (38.9%), and prior in the 7 remaining cases (12.9%). At the time of diagnosis 28 patients (51.8%) were asymptomatic and 26 (48.2%) had clinical features related to pheochromocytoma. In 6 patients (11.1%), the values of catecholamines and catabolites in urine were normal. In the cases with high values, the most useful isolated determination was that of metanephrines (82%), followed by adrenaline (76%). The CT scan did not provide a correct diagnosis in 6 patients with bilateral lesions, and one patient with a bilateral tumor was not diagnosed by MIBG. The combination of CT scan and MIBG diagnosed 100% of cases. The pheochromocytoma was bilateral in 27 cases, with a total number of 81 pathological glands detected. A laparascopic approach was used in 30 cases and a laparotomy in 24. The mean tumor size was 4.5 cm (range: 1-18 cm). Five patients with unilateral resection relapsed (18.5%), and the mean relapse time was 43.2 months (range: 12-120 months). There was a greater frequency of pheochromocytoma in those subjects who had the Cys634Arg mutation (p < 0.03). In addition, the Cys634Arg mutation is more frequent in bilateral cases. There are no prognostic factors for recurrence.


CONCLUSIONS
Pheochromocytoma in MEN 2A is related to the type of mutation, which can be early onset and is frequently asymptomatic. Its diagnosis requires catecholamines determinations as well as a CT scan. Correct diagnosis of bilaterality is established by CT and MIBG. Laparoscopic adrenalectomy is the treatment of choice.
Rodriguez
Jose M
JM
Endocrine Surgery Unit, Virgen de la Arrixaca University Hospital, 30120, Murcia, Spain. jmrodri@um.es
Balsalobre
Maria
M
Ponce
Jose L
JL
Ríos
Antonio
A
Torregrosa
Nuria M
NM
Tebar
Javier
J
Parrilla
Pascual
P
D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000601:surgery*; D000315:Adrenalectomy; D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005260:Female; D006801:Humans; D010535:Laparoscopy; D008297:Male; D008875:Middle Aged; D018813:Multiple Endocrine Neoplasia Type 2a / Q000150:complications* / Q000473:pathology / Q000628:therapy; D009154:Mutation / Q000235:genetics; D010673:Pheochromocytoma / Q000175:diagnosis* / Q000235:genetics / Q000601:surgery*; D051096:Proto-Oncogene Proteins c-ret / Q000235:genetics; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human
Nat Genet. 1994 Jan;6(1):70-4
7907913
N Engl J Med. 1999 Jun 17;340(24):1872-9
10369850
Surgery. 1993 Dec;114(6):1070-7
7903003
Radiographics. 2001 Jul-Aug;21(4):995-1012
11452074
N Engl J Med. 2002 May 9;346(19):1459-66
12000816
Eur J Endocrinol. 1996 Aug;135(2):222-5
8810737
Surgery. 1985 Aug;98(2):363-6
2862712
Surgery. 2000 Dec;128(6):1007-11;discussion 1011-2
11114636
J Intern Med. 1995 Oct;238(4):363-7
7595173
Clin Endocrinol (Oxf). 1993 May;38(5):531-7
8101147
Ann Surg. 2002 May;235(5):713-20; discussion 720-1
11981218
N Engl J Med. 1993 Nov 18;329(21):1531-8
8105382
Front Horm Res. 2004;31:121-44
14674308
Arch Surg. 2006 Dec;141(12):1199-205; discussion 1205
17178962
World J Surg. 2006 May;30(5):899-908
16617419
World J Surg. 1984 Aug;8(4):612-21
6148811
J Clin Endocrinol Metab. 2001 May;86(5):1999-2008
11344198
J Clin Endocrinol Metab. 2005 Jul;90(7):3999-4003
15827097
Ann N Y Acad Sci. 2002 Sep;970:41-53
12381540
J Clin Endocrinol Metab. 2004 Feb;89(2):479-91
14764749
JAMA. 1996 Nov 20;276(19):1575-9
8918855
Front Horm Res. 2004;31:45-60
14674304
J Clin Endocrinol Metab. 1999 Aug;84(8):2608-10
10443647
Clinics (Sao Paulo). 2006 Feb;61(1):59-70
16532227
Surgery. 1994 Dec;116(6):1101-9; discussion 1109-10
7985094
J Intern Med. 2005 Jan;257(1):60-8
15606377
Clin Endocrinol (Oxf). 1998 Feb;48(2):195-200
9579232
Front Horm Res. 2004;31:61-75
14674305
World J Surg. 1983 Mar;7(2):201-8
6135282
Eur J Endocrinol. 2001 Jan;144(1):37-44
11174835
Arq Bras Endocrinol Metabol. 2005 Oct;49(5):725-34
16444355
Surgery. 2007 Dec;142(6):800-5; discussion 805.e1
18063059
Ann Surg. 1993 Jun;217(6):595-601; discussion 601-3
8099474
J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71
11739416